What is ARA-290?
Described as an innate repair receptor agonist.
ARA-290 in the library · Healing & Repair Peptides · Human Trials · What are peptides?
2 registered trials · 5 indexed papers · 12 human / 14 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is
Described as an innate repair receptor agonist. It activates JAK-STAT signaling in endothelial cells and promotes vascular repair. (source: cited)
Registered human trials (2)
| Trial | Phase | Status | Year | Enrolled |
|---|---|---|---|---|
| Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis | Phase 2 | completed | 2014 | 64 |
| ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes) | Phase 2 | unknown | 2013 | 24 |
Peer-reviewed studies (5)
More cited research
- Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, t (2023, human observational)
- A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema (2020, human observational)
- Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression (2022, animal)
- Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation (2021, animal)
- Synthesis and evaluation of 99mTc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region (2021, animal)
- The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice (2021, animal)
Conditions researched
- Atherosclerosis, cardiovascular disease & high blood pressure
- Heart repair: after heart attack, heart failure & enlarged heart
- POTS and dysautonomia
- High cholesterol and statins
- Chronic and systemic inflammation
- Insulin resistance, prediabetes & type 2 diabetes
- Neuropathy and CRPS
Related compounds
- BPC-157
- L-Carnitine
- TB-500 (Thymosin Beta-4 fragment)
- ACTH (Corticotropin)
- Angiotensin II
- Bradykinin
- Cyanocobalamin (Vitamin B12)
- Endothelin-1
- Exenatide
- Glutathione
FAQ
What is ARA-290?
Described as an innate repair receptor agonist.
How many registered human trials study ARA-290?
The PeptideWhiz trial index lists 2 registered trials for ARA-290, the most recent from 2014.
How much published research exists on ARA-290?
The PeptideWhiz paper index links 5 PubMed papers to ARA-290; by study type, 12 human and 14 animal studies.
Which conditions is ARA-290 researched for?
Atherosclerosis, cardiovascular disease & high blood pressure, Heart repair: after heart attack, heart failure & enlarged heart, POTS and dysautonomia, High cholesterol and statins, Chronic and systemic inflammation, Insulin resistance, prediabetes & type 2 diabetes, Neuropathy and CRPS.
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).